Aurobindo Pharma Receives FDA Approval for Efavirenz Tablets

Strategic Insights -

Aurobindo Pharma Limited, a leading pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for Efavirenz tablets, 600 mg, marking the first generic approval of the company ahead of the rest of the industry. This significant development opens up a substantial opportunity for Aurobindo in Africa under the President's Emergency Plan for AIDS Relief (PEPFAR). Efavirenz, an antiretroviral (ARV) drug, is a crucial component in anti-AIDS therapy and will now be available for consideration for purchase under PEPFAR.

Key Takeaways:

  • Aurobindo Pharma Limited received approval from the US FDA for Efavirenz tablets, 600 mg, marking the company's first generic approval ahead of the rest of the industry.
  • Efavirenz, an ARV drug, is a key component in anti-AIDS therapy and will now be available for consideration under PEPFAR.
  • Efavirenz, also known as Sustiva, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that helps keep the AIDS virus from reproducing in cells.
  • The approval of Efavirenz tablets is significant for Aurobindo in Africa, where it will be used under the PEPFAR program.
  • PEPFAR, a 5-year program, aims to prevent seven million new HIV infections, treat at least two million HIV-infected people, and care for 10 million HIV-affected individuals, AIDS orphans, and vulnerable children.
  • The President's Emergency Plan for AIDS Relief (PEPFAR) is a $15 billion initiative announced by President Bush to combat the HIV/AIDS pandemic in 15 of the hardest-hit countries.

Statistics:

  • 600 mg: The strength at which Aurobindo Pharma's Efavirenz tablets have received FDA approval.
  • $15 billion: The amount allocated by PEPFAR to fight the HIV/AIDS pandemic over 5 years.
  • 5 years: The duration of the PEPFAR program aimed at preventing seven million new HIV infections and treating at least two million HIV-infected people.
  • 15 countries: The number of countries targeted by PEPFAR to combat the HIV/AIDS pandemic.
  • 10 million: The number of HIV-affected individuals, AIDS orphans, and vulnerable children to be cared for under PEPFAR.

Sources:

  • Aurobindo Pharma Limited's press release (date not specified)
  • NewsRx.com (2005)